Systematic review on the association between F2-isoprostanes and cardiovascular disease

Annals of Clinical Biochemistry

Volumn 50, Issue 2, 2013, Pages 108-114

  Zhang, Zhi Jiang ^a  

^a WUHAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ISOPROSTANE DERIVATIVE;

ANGIOCARDIOGRAPHY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY OBSTRUCTION; DISEASE ASSOCIATION; HUMAN; LIMB ISCHEMIA; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW;

CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; F2-ISOPROSTANES; HUMANS; PERIPHERAL ARTERIAL DISEASE; STROKE;

EID: 84879430023     PISSN: 00045632     EISSN: 17581001     Source Type: Journal    
DOI: 10.1258/acb.2012.011263     Document Type: Review

References (47)

1. Morrow JD, Hill KE, Burk RF, et al. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci USA 1990;87:9383-7
2. Morrow JD, Harris TM, Roberts LJ II. Noncyclooxygenase oxidative formation of a series of novel prostaglandins: analytical ramifications for measurement of eicosanoids. Anal Biochem 1990;184:1-10
3. Lawson JA, Rokach J, FitzGerald GA. Isoprostanes: formation, analysis and use as indices of lipid peroxidation in vivo. J Biol Chem 1999;274:24441-4
4. Roberts LJ, Morrow JD. Measurement of F(2)-isoprostanes as an index of oxidative stress in vivo. Free Radic Biol Med 2000;28:505-13
5. Kadiiska MB, Gladen BC, Baird DD, et al. Biomarkers of oxidative stress study II: are oxidation products of lipids, proteins, and DNA markers of CCl4 poisoning? Free Radic Biol Med 2005;38:698-710
6. Basu S. F2-isoprostanes in human health and diseases: from molecular mechanisms to clinical implications. Antioxid Redox Signal 2008;10:1405-34
7. Shao B, Heinecke JW. HDL, lipid peroxidation, and atherosclerosis. J Lipid Res 2009;50:599-601
8. Davies SS, Roberts LJ II. F2-isoprostanes as an indicator and risk factor for coronary heart disease. Free Radic Biol Med 2011;50:559-66
9. Waters DD, Alderman EL, Hsia J, et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA 2002;288:2432-40
10. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:23-33
11. Hercberg S, Galan P, Preziosi P, et al. The SU.VI.MAX Study: a randomized, placebo-controlled trial of the health effects of antioxidant vitamins and minerals. Arch Intern Med 2004;164:2335-42
12. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583-92
13. Willcox BJ, Curb JD, Rodriguez BL. Antioxidants in cardiovascular health and disease: key lessons from epidemiologic studies. Am J Cardiol 2008;101:75D-86D
14. Halliwell B, Lee CY. Using isoprostanes as biomarkers of oxidative stress: some rarely considered issues. Antioxid Redox Signal 13:145-56
15. Hou X, Roberts LJ II, Taber DF, et al. 2,3-Dinor-5,6-dihydro-15-F(2t)- isoprostane: a bioactive prostanoid metabolite. Am J Physiol Regul Integr Comp Physiol 2001;281:R391-400
16. Keaney JF Jr, Larson MG, Vasan RS, et al. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol 2003;23:434-9
17. Dimitrow PP, Undas A, Wolkow P, Tracz W, Dubiel JS. Enhanced oxidative stress in hypertrophic cardiomyopathy. Pharmacol Rep 2009;61:491-5
18. Roest M, Voorbij HA, Van der Schouw YT, et al. High levels of urinary F2-isoprostanes predict cardiovascular mortality in postmenopausal women. J Clin Lipidol 2008;2:298-303
19. Basarici I, Altekin RE, Demir I, Yilmaz H. Urinary 8-isoprostane levels can indicate the presence, severity and extent of angiographic coronary artery disease. Acta Cardiol 2008;63:415-22
20. Cipollone F, Ciabattoni G, Patrignani P, et al. Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina. Circulation 2000;102:1007-13
21. Delanty N, Reilly MP, Pratico D, et al. 8-epi PGF2 alpha generation during coronary reperfusion. A potential quantitative marker of oxidant stress in vivo. Circulation 1997;95:2492-9
22. Gross M, Steffes M, Jacobs DR Jr, et al. Plasma F2-isoprostanes and coronary artery calcification: the CARDIA Study. Clin Chem 2005;51:125-31
23. Noto D, Cottone S, Baldassare Cefalu A, et al. Interleukin 6 plasma levels predict with high sensitivity and specificity coronary stenosis detected by coronary angiography. Thromb Haemost 2007;98:1362-7
24. Ruef J, Marz W, Winkelmann BR. Markers for endothelial dysfunction, but not markers for oxidative stress correlate with classical risk factors and the severity of coronary artery disease (a subgroup analysis from the Ludwigshafen Risk and Cardiovascular Health Study). Scand Cardiovasc J 2006;40:274-9
25. Schwedhelm E, Bartling A, Lenzen H, et al. Urinary 8-iso-prostaglandin F2alpha as a risk marker in patients with coronary heart disease: a matched case-control study. Circulation 2004;109:843-8
26. Shishehbor MH, Zhang R, Medina H, et al. Systemic elevations of free radical oxidation products of arachidonic acid are associated with angiographic evidence of coronary artery disease. Free Radic Biol Med 2006;41:1678-83
27. Vassalle C, Botto N, Andreassi MG, Berti S, Biagini A. Evidence for enhanced 8-isoprostane plasma levels, as index of oxidative stress in vivo, in patients with coronary artery disease. Coron Artery Dis 2003;14:213-8
28. Wang B, Pan J, Wang L, et al. Associations of plasma 8-isoprostane levels with the presence and extent of coronary stenosis in patients with coronary artery disease. Atherosclerosis 2006;184:425-30
29. Wolfram R, Oguogho A, Palumbo B, Sinzinger H. Enhanced oxidative stress in coronary heart disease and chronic heart failure as indicated by an increased 8-epi-PGF(2alpha). Eur J Heart Fail 2005;7:167-72
30. Woodward M, Croft KD, Mori TA, et al. Association between both lipid and protein oxidation and the risk of fatal or non-fatal coronary heart disease in a human population. Clin Sci (Lond) 2009;116:53-60
31. Kelly PJ, Morrow JD, Ning M, et al. Oxidative stress and matrix metalloproteinase-9 in acute ischemic stroke: the Biomarker Evaluation for Antioxidant Therapies in Stroke (BEAT-Stroke) study. Stroke 2008;39:100-4
32. Lin CL, Hsu YT, Lin TK, et al. Increased levels of F2-isoprostanes following aneurysmal subarachnoid hemorrhage in humans. Free Radic Biol Med 2006;40:1466-73
33. Sanchez-Moreno C, Dashe JF, Scott T, et al. Decreased levels of plasma vitamin C and increased concentrations of inflammatory and oxidative stress markers after stroke. Stroke 2004;35:163-8
34. Ward NC, Croft KD, Blacker D, et al. Cytochrome P450 metabolites of arachidonic acid are elevated in stroke patients compared with healthy controls. Clin Sci (Lond) 2011;121:501-7
35. Kals J, Kampus P, Kals M, et al. Inflammation and oxidative stress are associated differently with endothelial function and arterial stiffness in healthy subjects and in patients with atherosclerosis. Scand J Clin Lab Invest 2008;68:594-601
36. Mueller T, Dieplinger B, Gegenhuber A, et al. Serum total 8-iso-prostaglandin F2alpha: a new and independent predictor of peripheral arterial disease. J Vasc Surg 2004;40:768-73
37. Rossi P, Riutta A, Kuukasjarvi P, et al. Revascularization decreases 8-isoprostaglandin F2alpha excretion in chronic lower limb ischemia. Prostaglandins Leukot Essent Fatty Acids 2004;71:97-101
38. Wu T, Rifai N, Roberts LJ II, Willett WC, Rimm EB. Stability of measurements of biomarkers of oxidative stress in blood over 36 hours. Cancer Epidemiol Biomarkers Prev 2004;13:1399-402
39. Lee CY, Jenner AM, Halliwell B. Rapid preparation of human urine and plasma samples for analysis of F2-isoprostanes by gas chromatography-mass spectrometry. Biochem Biophys Res Commun 2004;320:696-702
40. Liu W, Morrow JD, Yin H. Quantification of F2-isoprostanes as a reliable index of oxidative stress in vivo using gas chromatography-mass spectrometry (GC-MS) method. Free Radic Biol Med 2009;47:1101-7
41. Wiswedel I. F(2)-isoprostanes: sensitive biomarkers of oxidative stress in vitro and in vivo: a gas chromatography-mass spectrometric approach. Methods Mol Biol 2009;580:3-16
42. Tsikas D, Schwedhelm E, Suchy MT, et al. Divergence in urinary 8-iso-PGF(2alpha) (iPF(2alpha)-III, 15-F(2t)-IsoP) levels from gas chromatography-tandem mass spectrometry quantification after thin-layer chromatography and immunoaffinity column chromatography reveals heterogeneity of 8-iso-PGF(2alpha). Possible methodological, mechanistic and clinical implications. J Chromatogr B Analyt Technol Biomed Life Sci 2003;794:237-55
43. Sicilia T, Mally A, Schauer U, Pahler A, Volkel W. LC-MS/MS methods for the detection of isoprostanes (iPF2alpha-III and 8,12-iso-iPF2alpha-VI) as biomarkers of CCl4-induced oxidative damage to hepatic tissue. J Chromatogr B Analyt Technol Biomed Life Sci 2008;861:48-55
44. Proudfoot J, Barden A, Mori TA, et al. Measurement of urinary F(2)-isoprostanes as markers of in vivo lipid peroxidation-A comparison of enzyme immunoassay with gas chromatography/mass spectrometry. Anal Biochem 1999;272:209-15
45. Il'yasova D, Morrow JD, Ivanova A, Wagenknecht LE. Epidemiological marker for oxidant status: comparison of the ELISA and the gas chromatography/mass spectrometry assay for urine 2,3-dinor- 5,6-dihydro-15-F2t-isoprostane. Ann Epidemiol 2004;14:793-7
46. Saenger AK, Laha TJ, Edenfield MJ, Sadrzadeh SM. Quantification of urinary 8-iso-PGF2alpha using liquid chromatography-tandem mass spectrometry and association with elevated troponin levels. Clin Biochem 2007;40:1297-304
47. Bessard J, Cracowski JL, Stanke-Labesque F, Bessard G. Determination of isoprostaglandin F2alpha type III in human urine by gas chromatography-electronic impact mass spectrometry. Comparison with enzyme immunoassay. J Chromatogr B Biomed Sci Appl 2001;754:333-43